ATRX is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].